ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
CI
Catalan Institute of Oncology (ICO) at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Catalan Institute of Oncology (ICO) takes part in 16 sessions at ESMO 2026 in Madrid. Its work covers treatment choices and outcomes across several cancers, with attention to biomarkers and personalized care. It explores which patients with locally advanced rectal cancer may achieve a complete response and preserve the organ.
| Organization | ESMO 2026 Attendance |
|---|---|
CI Catalan Institute of Oncology (ICO) L'Hospitalet de Llobregat, Spain | |
Public cancer centre of the Catalan health system, with its main hospital in L'Hospitalet de Llobregat near Barcelona, Spain. | Poster Fri Oct 23 13:00–15:00 A phase 2, multicenter study of TILs treatment in germ cell tumors: The ARES study Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Dynamic GDF15 and systemic nutritional vulnerability in oropharyngeal cancer Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Genomic landscape of prostate cancer bone metastases progressing on androgen receptor pathway inhibitors and association with overall survival Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Transcriptomic dissection of metastatic uveal melanoma identifies survival-linked biological programs Melanoma & skin cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Sat Oct 24 12:00–12:45 Cytoreductive surgery following tebentafusp (tebe) in metastatic uveal melanoma (mUM): A proof-of-concept case series with translational analysis Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Phase I/II study of ICOVIR-5 with allogeneic mesenchymal stem cells (AloCelyvir) in metastatic uveal melanoma (PULSE-UM) Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 13:35–14:05 Treatment evolution in mHSPC: Who needs treatment intensification? Genitourinary cancers Talk Sat Oct 24 16:00–16:15 Satellite Sat Oct 24 18:30–20:00 Satellite Sat Oct 24 18:30–18:35 Chair’s welcome and introductions Lung & thoracic cancers Satellite Sat Oct 24 18:55–19:05 HER2 across cancers: Unlocking broader therapeutic potential Lung & thoracic cancers Satellite Sat Oct 24 19:55–20:00 Chair’s closing remarks Lung & thoracic cancers Chair Sun Oct 25 10:15–11:30 Evolving treatment paradigms in nasopharyngeal carcinoma Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 10:15–10:20 Presentation of case/condition Sarcoma, CNS, head & neck and rare cancers Poster Sun Oct 25 12:00–12:45 Prospective study in faecal liquid biopsy of the predictive value of methylation, microbiome, and diet in locally advanced rectal cancer (LARC) eligible for neoadjuvant therapy: EMELARC project Gastrointestinal cancersBiomarkers & precision oncology Abstract Sun Oct 25 14:45–14:50 LBA46 - Niraparib and dostarlimab plus radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients (TTCC-2022-01 RADIAN) Sarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 14:45–16:15 Rapid oral: Head and neck cancer Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 15:54–16:06 Invited Discussant LBA47, 1538RO and 1541RO Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Long-term outcomes and prognostic factors in conventional chondrosarcoma: A single reference-center cohort Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 |
Find decision makers at Catalan Institute of Oncology (ICO)
Tell us what you sell and we’ll find the people at Catalan Institute of Oncology (ICO) most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction